Trade SYRE stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Spyre Therapeutics, Inc. (SYRE) is trading at US$102.91, down 3.66% today as of Nov 12, 16:00 EST. The company has a market capitalisation of US$9.24B. Over the past 52 weeks, SYRE has traded between US$22.13 and US$110.64. On Syfe you can trade SYRE with $0 commission and add it to your watchlist.
| Previous close | US$106.82 |
|---|---|
| Market cap | US$9.24B |
| 52-week range | US$22.13 – US$110.64 |
| Volume | 977.68K |
| Exchange | US |
Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Year: 2016
UBS Initiates Spyre Therapeutics at Buy With $120 Price Target
Oct 12, 11:44 AM · MT Newswires
Update: Spyre Shares Fall After Pricing $350 Million Stock Offering
Oct 6, 7:56 PM · MT Newswires
Spyre Therapeutics, Inc. (SYRE) stock is trading at US$102.91, -3.66% from the previous close of US$106.82.
The market cap for Spyre Therapeutics, Inc. (SYRE) stock is approximately US$9.24B.
The 52-week high for Spyre Therapeutics, Inc. (SYRE) stock is US$110.64.
The 52-week low for Spyre Therapeutics, Inc. (SYRE) stock is US$22.13.
Spyre Therapeutics, Inc. (SYRE) does not currently pay a dividend.
Stay on top of SYRE
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
